Altimmune

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Altimmune and other ETFs, options, and stocks.

About ALT

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.

CEO

Vipin K. Garg

CEOVipin K. Garg

Employees

Employees59

Headquarters

Gaithersburg, Maryland

HeadquartersGaithersburg, Maryland

Founded

1997

Founded1997

Employees

Employees59

ALT Key Statistics

Market cap

317.28M

Market cap317.28M

Price-Earnings ratio

-3.05

Price-Earnings ratio-3.05

Dividend yield

—

Dividend yield—

Average volume

1.92M

Average volume1.92M

High today

$3.60

High today$3.60

Low today

$3.59

Low today$3.59

Open price

$3.63

Open price$3.63

Volume

14.15K

Volume14.15K

52 Week high

$11.16

52 Week high$11.16

52 Week low

$2.90

52 Week low$2.90

ALT News

TipRanks 21h

Altimmune’s Pemvidutide Advances: Analyst Recommends Buy with Promising Trial Milestones and Dual Mechanism Benefits

Altimmune, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on...

TipRanks 1d

Altimmune appoints Richardson as Chief Commercial Officer

Altimmune (ALT) announced the appointment of Linda Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Richardson joins the Compan...

Analyst ratings

80%

of 10 ratings

Buy

80%

Hold

10%

Sell

10%

People also own

Based on the portfolios of people who own ALT. This list is generated using Robinhood data, and it’s not a recommendation.